Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Comparison of the Everolimus Eluting (XIENCE-V, XIENCE-Prime or PROMUS Stent) With the Biolimus A9 Eluting NOBORI Stent in All-comers: a Randomized Open Label Study The COMPARE II Trial Imaging and Vasomotion Substudy.

Next Previous
Trial Profile

Comparison of the Everolimus Eluting (XIENCE-V, XIENCE-Prime or PROMUS Stent) With the Biolimus A9 Eluting NOBORI Stent in All-comers: a Randomized Open Label Study The COMPARE II Trial Imaging and Vasomotion Substudy.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 21 May 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Everolimus (Primary) ; Umirolimus (Primary)
  • Indications Cardiovascular disorders; Coronary artery disease; Coronary artery restenosis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms COMPARE-II

Most Recent Events

  • 02 Nov 2017 Pooled results of COMPARE II, RAI and MAASSTAD-ABSORB studies, comparing the outcomes of Bioresorbable Vascular Scaffold versus a 2nd generation metallic stent in the patients with Small vessel disease presented at the 29th Annual Scientific Symposium on Transcatheter Cardiovascular Therapeutics.
  • 01 Nov 2016 Results of five years follow-up of patients with ST-segment elevation (n=568) published in the Journal of the American College of Cardiology
  • 30 Jan 2013 Results published in the Lancet.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top